What are the generic drugs of Quizartinib and their information?

The original drug Quizartinib is used in many places around the world to treat adult patients with FLT3-ITD-positive acute myeloid leukemia (AML). As the patent protection period gradually expires, some overseas pharmaceutical companies have launched generic versions to meet different market needs. The main feature of generic drugs is that their drug ingredients are basically the same as the original drugs, but there may be differences in packaging, specifications and price.

For example, the generic version of Quizartinib produced by Lucius Pharmaceuticals of Laos has been launched in some international markets, and its packaging specifications are usually 14 tablets per box. In terms of price, it is about more than 1,000 yuan per box, but the specific cost will be adjusted due to exchange rate fluctuations and regional differences. The emergence of generic drugs provides relatively economical treatment options for some patients, while maintaining similar pharmacological effects and clinical effects to the original drugs.

When using generic drugs, clinicians usually evaluate the drug's quality, source, and the patient's own treatment needs to ensure that the generic drug can be a safe and effective substitute for the brand-name drug. Like original drugs, generic drugs also need to strictly follow dosage, treatment duration and monitoring requirements, especially in terms of electrocardiogram, hematological indicators and possible adverse reaction management, to ensure consistent treatment safety and efficacy.

Overall, the launch of generic drugs of Quizartinib provides more affordable treatment options for AML patients around the world, especially in resource-limited areas. This not only helps expand treatment coverage, but also promotes accessibility and equality in leukemia treatment around the world. The development trend of generic drugs shows that in the future, more patients will have the opportunity to obtain the precise treatment benefits brought by targeted therapies without economic factors limiting treatment options.

Keyword tag: Quizartinib Generic drugs Quizartinib AML leukemia FLT3-ITD targeted therapy drug economics price information

References：https://www.ema.europa.eu/en/medicines/human/EPAR/vanflyta